"Prix Galien represents a pinnacle of achievement for the men and women committed to curing disease and improving health through the development of innovative medicines."
Professor Sir Michael Rawlins, Chair, MHRA

The Prix Galien Awards were established to recognise and promote significant advances in pharmaceutical research. They honour medical research, pharmacology and pharmaceutical innovation, celebrating outstanding efforts to improve the human condition through the development of novel, high-value medicines.
Prix Galien Awards are the only independent awards of their kind across the global industry. Judged by eminent healthcare leaders and specialists. The best, judged by the very best.
UK Prix Galien Awards are held biennially at the Houses of Parliament, Palace of Westminster, London. They are managed by healthcare business intelligence specialists ValueBase.
Prix Galien is a global brand with national awards in France, Germany, US, Italy, Spain, Belgium, Luxemburg, Portugal, Canada, Switzerland, Poland, Israel, Greece, Russia and Morocco.
The Prix Galien Awards, founded in France in 1969, are named after the ancient Roman philosopher and teacher Claudius Galenus (AD 131-201), generally acknowledged as the 'father of modern pharmacology'.
About UK Prix Galien

“I am glad to congratulate all those that promote the Prix Galien and pharmaceutical research: they play a key role in the fight against diseases across the world.” John Major, former Prime Minister, United Kingdom

The 2016 UK Prix Galien Awards were held at the Houses of Parliament, London on Wednesday 21st September 2016. Applicants were invited to register for entry between October 2015 and 29th February 2016, with final submissions required by 29th April 2016.

There were three Award categories:

Innovative Product Award for innovative new medicines launched or granted a new indication in the UK market during the period 1st January 2014 to 31st March 2016. Products granted marketing authorisation through EU centralised procedure, in the UK or available under the mutual recognition process were admissible.
Orphan Product Award for innovative new products granted Orphan Drug status in the European Union and/or the US, launched or granted a new indication in the UK market during the period 1st January 2014 to 31st March 2016. Orphan Product Award for innovative new products granted Orphan Drug status in the European Union and/or the US, launched or granted a new indication in the UK market during the period 1st January 2014 to 31st March 2016.
Real World Evidence Award - new for 2016 - recognising excellence in the generation, collection and application of observational data to demonstrate health outcomes, real-world patient benefits or socio-economic gains in licensed medicines. For previous UK Prix Galien winners and commended products only.

"Prix Galien is a welcome initiative to stimulate creative research and promote excellence." Barack Obama, President of the United States of America

Novartis, Astellas and Chiesi win Prix Galien Prizes on night of firsts for UK pharma

London, 21st September, 2016. The first new treatment for heart failure in 15 years and Europe's first approved stem cell therapy have scooped top prizes at the 2016 UK Prix Galien Awards.

2016 UK Prix Galien opens for entries

November, 2015, London: Entries have opened for the 2016 UK Prix Galien Awards, the highest accolade for pharmaceutical research and development.

2016 UK Prix Galien shortlist revealed

London, 29th June, 2016. Treatments for lung cancer, ulcerative colitis, heart failure and idiopathic pulmonary fibrosis are among 16 innovations shortlisted for one of the most prestigious prizes in pharmaceutical R&D – a Prix Galien medal.

Past winners

“The Prix Galien is a very special Award that honors the pharmaceutical and biotechnology industries for landmark achievements in the development of Pharmaceuticals.” Bengt Samuelsson, Nobel Laureate, Chairman of the Nobel Foundation

The UK Prix Galien Hall of Fame is home to the chosen few. But, in the 25 years since the UK Awards were introduced, some of the industry’s biggest brands have won a coveted Prix Galien medal:

Zofran, Glaxo
Eprex, Cilag


Octreotide, Novartis
Zocor, MSD
Neupogen, Amgen/Roche


Proscar, MSD
Exosurf, Wellcome


Havrix, SmithKline Beecham


Tagamet, SmithKline Beecham


Invirase, Roche
Lamictal, Glaxo Wellcome


Zovirax, Glaxo Wellcome


Zyprexa, Eli Lilly


Singulair, MSD


Viagra, Pfizer
Meningitec, Wyeth


Herceptin, Roche
Glivec, Novartis


Fuzeon, Roche
Prevenar, Wyeth


Xolair, Novartis
Rotarix, GSK
Myozyme, Genzyme
(Orphan category)


Cervarix, GSK
Gardasil, SPMSD
Exjade, Novartis (Orphan category)


Xarelto, Bayer Schering
Firazyr, Shire Pharmaceuticals
(Orphan category)


Incivo, Janssen
Victrelis, MSD
Mepact, Takeda UK (Orphan category)


Bexsero, Novartis
Sirturo, Janssen (Orphan category)


Entresto, Novartis
Holoclar, Chiesi (Orphan category)
Dificlir, Astellas (Real World Evidence category)

Prix Galien around the world

"The Prix Galien brings appropriate recognition to numerous scientists and clinicians in the pharmaceutical industry who have contributed enormously to the battle against human diseases." Paul GREENGARD, Nobel Laureate

The importance of Prix Galien has helped cement its reputation as the highest accolade in pharmaceutical research all over the world.

Prix Galien: a global language of excellence


"The Galien Award is a remarkable distinction which enables us to crown significant efforts in the field of pharmaceutical research and plays an important role for our health."


"Prix Galien recognizes the excellence of the pharmaceutical industry."


"The Prix Galien: a prestigious testimony and acknowledgment of the vitality of our pharmaceutical research. "

The Netherlands

"The Prix Galien is the highest distinction which can be awarded to a therapeutic innovation."


"The Prix Galien is considered as the Nobel prize of pharmaceutical research. It testifies to its recipients the excellence and quality of the rewarded drug."


"The Galien Award can be considered as … a Nobel Prize for pharmaceutical research."


"When Olympianism rimes with Galienism: there is a gold medal which can be won on account of our performance: it is the Prix Galien, the academy Award of pharmaceutical research."


"Prix Galien show that pharmaceutical innovation is aligned with many of the priority needs identified in the NHS Outcomes Framework."
Prix Galien Judges

"I thank the Prix Galien for recognising that a healthier world is a safer world and a more just world." Ban Ki Moon, Secretary-General, United Nations

UK Prix Galien Awards are judged by an independent panel of experienced and eminent healthcare leaders. The judges are all high-achieving, influential stakeholders who have shaped, and are still shaping, healthcare in the UK. Their support is an endorsement of the Prix Galien brand. The 2016 judges include:

Professor Sir Michael Rawlins

Sir Michael is Chairman of the Medicines and Healthcare products Regulatory Agency (since December 2014). He is a Clinical Phamacologist and Specialist in Internal Medicine. He was Professor of Clinical Pharmacology in Newcastle, and Physician at the Newcastle Hospitals, from 1999-2006.

He was Chairman of the Committee on Safety of Medicines (1992-1998), Chairman of the Advisory Council on the Misuse of Drugs (1998-2008) and founding Chairman of the National Institute for Clinical Excellence (1999-2013). He is recent past President of the Royal Society of Medicine (2012-2014).

Currently Sir Michael is Chairman of UK Biobank, Honorary Professor at the London School of Hygiene and Tropical Medicine, and Emeritus Professor at the University of Newcastle upon Tyne.

Sir Michael was appointed the Chairman of the Medicines and Healthcare products Regulatory Agency (MHRA) on 1st December 2014.

Professor Parveen Kumar

Professor Kumar is Professor of Medicine and Education, Barts & the London School of Medicine & Dentistry, Queen Mary University of London. Honorary Consultant Physician and Gastroenterologist, Barts & The London NHS Trust and Homerton University Hospital Foundation Trust. 

Professor Kumar's research interests have been in disorders of the small bowel, particularly coeliac disease. She was a Non-Executive Director of the National Institute of Clinical Excellence, and Chairman of the Medicines Commission UK. She has been Vice President for the Royal College of Physicians, President of the British Medical Association and President of the Royal Society of Medicine. She was also the Director of CPD, Associate Director for International Education for the RCP. She is currently a trustee of the British Society of Gastroenterology, President of the Royal Medical Benevolent Fund and President- Elect for the Medical Women's Federation.  She is on the International Advisory Board for SACORE (Southern African Consortium for Research Excellence). She was a trustee of Tropical Health and Education Trust (THET), Chairman of the BMJ eLearning board and also of the BUPA Foundation charity for research. 

Professor Kumar co-edits ‘Kumar and Clark's Clinical Medicine’, a textbook for students and doctors, which is used worldwide, as well as other books. She was awarded CBE for services to medicine in 2001.

Dr Jane Adam

Dr Adam chairs one of the Technology Appraisal committees of the National Institute of Care Excellence. She is also a Consultant Radiologist at St. George’s Hospital, London, with a special interest in imaging of diseases of the ear, nose and throat. 

She is former founding Chair of the European Society of Radiology Audit and Standards Committee and currently chairs the ESR Quality, Safety and Standards Committee and is a Member of the Executive Committee. 

Dr Adam has been a member of the Council of the Royal College of Radiologists, RCR lead for revalidation and has chaired various other College committees. She has a long-standing interest in standard setting and evaluation and has lectured nationally and internationally on these subjects.

Dr Amanda Adler

Dr Adler chairs a Technology Appraisal Committee with the National Institute for Health and Care Excellence. Also with NICE, she chaired the National Guidelines Committee for Newer Agents for Type 2 Diabetes and the Quality Standard for Diabetes for England.

A consultant physician at the Institute of Metabolic Sciences at Addenbrooke’s Hospital in Cambridge, Dr Adler practices diabetes and general medicine in the in-patient, out-patient and community settings. Previously, she was Clinical Epidemiologist for the UK Prospective Diabetes Study at Oxford University.

Dr Adler is a Fellow of the Royal College of Physicians, and has helped the MHRA and EMA in issues related to the safety of drugs for diabetes.

Professor Stephen Evans

Stephen Evans is Professor of Pharmacoepidemiology at the London School of Hygiene and Tropical Medicine (LSHTM) and is a medical statistician.

Stephen was at the UK Medicines Control Agency (now the MHRA) from 1995 to 1999, and 2000-2002. While at the MCA he dealt with major safety issues such as HRT and breast cancer; vitamin K and childhood cancer; MMR and autism.

After training in Physics and Computing, he joined The London Hospital in 1970 becoming Professor of Medical Statistics in 1990.

He is or has been on various editorial boards, including the British Journal of Clinical Pharmacology and is an Associate Editor of Pharmaco-epidemiology and Drug Safety. He has been a statistical advisor to the British Medical Journal and a member of its editorial review committee for over 15 years. He is an independent expert member of the European Medicines Agency’s committee that deals with drug safety (PRAC), and was a member of the WHO Global Advisory Committee on Vaccine Safety. He is an Honorary fellow of The Royal College of Physicians of London.

Dr Mark Porter

Dr Porter is a practising GP, working part time at his NHS practice in South Gloucestershire and spending the rest of his week writing and broadcasting on health consumer issues.

He qualified from Westminster Hospital Medical School, London, in 1986 and spent five years in a variety of hospital specialities before entering General Practice.

Mark presents BBC Radio 4’s flagship medical series Inside Health and is medical columnist at The Times and doctor on the One Show. He was appointed MBE for services to medicine in 2005.

Dr June Raine

Dr Raine trained in general medicine in Oxford after completing a Masters degree by research in Pharmacology.  Her interest in drug safety led to a career in medicines regulation which has spanned a number of roles in assessment, management and strategic development within the UK national authority.

Appointed in 1999 to head Pharmacovigilance in the Medicines Control Agency (now Medicines and Healthcare products Regulatory Agency), she was elected in 2005 to chair the EU Pharmacovigilance Working Party and in 2012 as the first chair of the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee.  She is also a member of the WHO Advisory Committee on Safety of Medicinal Products and a board member of the International Society for Pharmacoepidemiology.

Dr Raine has a special interest in strengthening the evidence base for regulatory decision-making and she has driven forward the use of pharmacoepidemiological methodologies in pharmacovigilance, including use of the UK’s Clinical Practice Research Datalink.   Her current interests include monitoring the outcomes of regulatory action, risk communication and patient involvement in the regulatory process.

Professor Sir Mike Richards

Sir Mike was a hospital physician for over 20 years. After a variety of training posts he was a Consultant Medical Oncologist (1986-1995) and Professor of Palliative Medicine (1995-1999) at Guy’s and St. Thomas’ Hospitals. 

In 1999 he was appointed as the first National Cancer Director at the Department of Health. In 2007 his role was extended to incorporate end of life care. He led the development and implementation of the NHS Cancer Plan (2000), the Cancer Reform Strategy (2007), the End of Life Care Strategy (2008) and Improving Outcomes: A Strategy for Cancer (2011). 

In July 2012 Sir Mike was appointed as Director for Reducing Premature Mortality in the NHS Commissioning Board (now NHS England). In this role he led the development of a cardiovascular outcomes strategy. 

In July 2013 he took up the post of Chief Inspector of Hospitals at the Care Quality Commission. He was appointed CBE in 2001 and was awarded a Knighthood in 2010.

Professor Philip Routledge

Professor Routledge is an Honorary Consultant Physician and Clinical Pharmacologist in Cardiff and Vale University Health Board, and Head of the Department of Pharmacology, Therapeutics and Toxicology in Cardiff University School of Medicine.

He has served on several MHRA regulatory committees, including the Medicines Commission UK, and on appraisal committees of NICE. He was appointed first Chairman of the newly-formed UK Herbal Medicines Advisory Committee in 2005, and from 2006 until 2014, served as Chairman of the All-Wales Medicines Strategy Group (AWMSG). He is also a member of the Bevan Commission, an impartial advisory group to the Minister for Health and Social Services (and other Welsh Government Ministers).

Professor Routledge is a President Emeritus of the British Pharmacological Society, an Honorary Fellow of the Royal College of General Practitioners, the Royal Society of Biology and the Faculty of Pharmaceutical Medicine. He was appointed Officer of the Order of the British Empire (OBE) in 2008 for services to medicine.

Professor Liam Smeeth

Professor Smeeth is Professor of Clinical Epidemiology and Head of the Department of Non-communicable Disease Epidemiology at the London School of Hygiene and Tropical Medicine. He also undertakes clinical work as a General Practitioner in north London and is involved in a wide range of activities for the National Health Service.

Much of his research is based on making better use of computerised clinical data both to investigate drug effects and disease aetiology. He holds a Wellcome Trust Senior Fellowship in Clinical Science and is Deputy Director of the Farr Institute London, one of the four UK Health Informatics Research Centres. His broad interests include disease aetiology, drug effects, genetics and non-communicable diseases in low income settings

Professor Simon Thomas

Professor Thomas is a Consultant Physician at the Newcastle Hospitals NHS Foundation Trust and Professor of Clinical Pharmacology and Therapeutics at Newcastle University, Director, National Poisons Information Service (Newcastle) Unit and the UK Teratology Information Service. 

Professor Thomas is a member of the Commission for Human Medicines and the Advisory Council on the Misuse of Drugs Technical Subcommittee. He is immediate Past President of the European Association of Poisons Centres and Clinical Toxicologists and chair of the National Poisons Information Service Clinical Standards Group.

He trained at St Thomas’s Hospital in London, the Freeman Hospital in Newcastle and at Newcastle University. His research interests include adverse drug reactions, especially drug-induced arrhythmia, poisoning and clinical toxicology. He has published extensively on ECG abnormalities, arrhythmias and sudden death associated with drug therapy, especially antipsychotic agents.

Professor David J Webb

Professor Webb is a physician and pharmacologist based at the Queen’s Medical Research Institute and Royal Infirmary of Edinburgh. He led Edinburgh’s Cardiovascular Research Initiative and University Centre for Cardiovascular Science, and currently directs the Translational Medicine and Therapeutics Initiative (STMTI) and is pharmacology lead for the Scottish MRC Clinical Pharmacology and Pathology Programme. He leads Edinburgh’s Hypertension Excellence Centre, and his research is on the pathophysiology of hypertension, particularly focused on the role of the vascular endothelium and renal disease. 

In Scotland, he has been President of the Scottish Society of Physicians and Chairman of the Scottish Medicines Consortium (SMC), having been chair of its New Drugs Committee, and previously involved in SMC’s creation.

Professor Webb is currently President of BPS, having previously held the roles of Vice-President Meetings and President-Elect. He is also currently a Non-Executive Director of the Medicines and HealthCare products Regulatory Agency (MHRA) and Chair of the Scientific Advisory Committee for the National Institute for Biological Standards and Control (NIBSC). He is Honorary President of the European Association for Clinical Pharmacology and Therapeutics and Vice Chair of the Clinical Division of the International Union of Basic and Clinical Pharmacology (IUPHAR). He is a Fellow of the Royal Society of Edinburgh and of the Academy of Medical Sciences, where he has been involved in Working Groups on Safer Medicines, the Regulation and Governance of Medical Research, and Methods of Evaluating Evidence.


"Thank you for being here, for your great labors and for the success." Bill Clinton, former President of the United States of America

To find out more about UK Prix Galien, why not download our FAQs? or drop us a line at info@prixgalien.co.uk

Or contact ValueBase, owners of the UK Prix Galien franchise.

Follow us on